Guidance for clinical and public health laboratories testing for influenza virus antiviral drug susceptibility in Europe

Journal of Clinical Virology

Volumn 57, Issue 1, 2013, Pages 5-12

  Pozo, Francisco ^a   Lina, Bruno ^b   Andrade, Helena Rebelo de ^c   Enouf, Vincent ^d   Kossyvakis, Athanasios ^e   Broberg, Eeva ^f   Daniels, Rod ^g   Lackenby, Angie ^h   Meijer, Adam ⁱ  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HCL   (France)

^c RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^d INSTITUT PASTEUR   (France)

^e HELLENIC PASTEUR INSTITUTE   (Greece)

^f EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

^g NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^h PUBLIC HEALTH ENGLAND   (United Kingdom)

ⁱ NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Antiviral drugs; Guidance; Influenza; Susceptibility testing

Indexed keywords

AMANTADINE; ION CHANNEL; OSELTAMIVIR; RIMANTADINE; VIRUS SIALIDASE; ZANAMIVIR;

AMINO ACID SUBSTITUTION; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; ARTICLE; CLINICAL DECISION MAKING; ENZYME INHIBITION; EUROPE; GENOTYPE; HUMAN; INFECTION CONTROL; INFLUENZA A; INFLUENZA B; INFLUENZA VIRUS; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; LABORATORY TEST; NONHUMAN; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH; SEASONAL INFLUENZA;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA, HUMAN; MICROBIAL SENSITIVITY TESTS; ORTHOMYXOVIRIDAE; QUALITY ASSURANCE, HEALTH CARE; VIROLOGY;

EID: 84875812074     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2013.01.009     Document Type: Article

References (38)

1. Hurt A.C., Chotpitayasunondh T., Cox N.J., Daniels R., Fry A.M., Gubareva L.V., et al. Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect Dis 2012, 12:240-248.
2. Meijer A., Lackenby A., Hay A., Zambon M. Influenza antiviral susceptibility monitoring activities in relation to national antiviral stockpiles in Europe during the winter 2006/2007 season. Euro Surveill 2007, 12:E3-E4.
3. Nguyen H.T., Fry A.M., Gubareva L.V. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. Antivir Ther 2012, 17(1 Pt B):159-173.
4. Tisdale M. Influenza M2 Ion-channel and neuraminidase inhibitors. Antimicrobial Drug Resistance, Volume 1, Mechanisms of Drug Resistance 2009, 421-447. Springer, Dordrecht, Heidelberg, London, New York. D.L. Mayers, S.A. Lerner, M. Ouellette, J.D. Sobel (Eds.).
5. Kawai N., Ikematsu H., Hirotsu N., Maeda T., Kawashima T., Tanaka O., et al. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons. Clin Infect Dis 2009, 49:1828-1835.
6. World Health Organization Meetings of the WHO working group on surveillance of influenza antiviral susceptibility-Geneva, November 2011 and June 2012. Wkly Epidemiol Rec 2012, 39:369-374.
7. Ferraris O., Lina B. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. J Clin Virol 2008, 41:13-19.
8. Lackenby A., Thompson C.I., Democratis J. The potential impact of neuraminidase inhibitor resistant influenza. Curr Opin Infect Dis 2008, 21:626-638.
9. Shiraishi K., Mitamura K., Sakai-Tagawa Y., Goto H., Sugaya N., Kawaoka Y. High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. J Infect Dis 2003, 188:57-61.
10. Dutkowski R. Oseltamivir in seasonal influenza: cumulative experience in low- and high-risk patients. J Antimicrob Chemother 2010, 65(Suppl. 2):ii11-ii24.
11. Garg S., Fry A.M., Patton M., Fiore A.E., Finelli L. Antiviral treatment of influenza in children. Pediatr Infect Dis J 2012, 31:e43-e51.
12. Varner M.W., Rice M.M., Anderson B., Tolosa J.E., Sheffield J., Spong C.Y., et al. Influenza-like illness in hospitalized pregnant and postpartum women during the 2009-2010 H1N1 pandemic. Obstet Gynecol 2011, 118:593-600.
13. Hurt A.C., Hardie K., Wilson N.J., Deng Y.M., Osbourn M., Gehrig N., et al. Community transmission of oseltamivir-resistant A(H1N1)pdm09 influenza. N Engl J Med 2011, 365:2541-2542.
14. Lackenby A., Hungnes O., Dudman S.G., Meijer A., Paget W.J., Hay A.J., et al. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill 2008, 13. [pii=8026].
15. Hauge S.H., Dudman S., Borgen K., Lackenby A., Hungnes O. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg Infect Dis 2009, 15:155-162.
16. Meijer A., Lackenby A., Hungnes O., Lina B., van der Werf S., Schweiger B., et al. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg Infect Dis 2009, 15:552-560.
17. Dharan N.J., Gubareva L.V., Meyer J.J., Okomo-Adhiambo M., McClinton R.C., Marshall S.A., et al. Oseltamivir-Resistance Working Group, Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 2009, 301:1034-1041.
18. García J., Sovero M., Torres A.L., Gomez J., Douce R., Barrantes M., et al. Antiviral resistance in influenza viruses circulating in Central and South America based on the detection of established genetic markers. Influenza Other Respir Viruses 2009, 3:69-74.
19. Hurt A.C., Ernest J., Deng Y.M., Iannello P., Besselaar T.G., Birch C., et al. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res 2009, 83:90-93.
20. Thorlund K., Awad T., Boivin G., Thabane L. Systematic review of influenza resistance to the neuraminidase inhibitors. BMC Infect Dis 2011, 11:134.
21. Lackenby A., Moran Gilad J., Pebody R., Miah S., Calatayud L., Bolotin S., et al. Continued emergence and changing epidemiology of oseltamivir-resistant influenza A(H1N1)2009 virus, United Kingdom, winter 2010/11. Euro Surveill 2011, 16. [pii=19784. Erratum in: Euro Surveill 2011;16:pii=19789].
22. Meijer A., Jonges M., van Beek P., Swaan C., Osterhaus A., Daniels R., et al. Oseltamivir-resistant influenza A(H1N1)pdm09 virus in Dutch travellers returning from Spain, August 2012. Euro Surveill 2012, 17. [pii=20266].
23. Malato L., Llavador V., Marmier E., Youssef J., Balick Weber C., Rozé H., et al. Pandemic influenza A(H1N1) 2009 molecular characterisation and duration of viral shedding in intensive care patients in Bordeaux, south-west France, May 2009 to January 2010. Euro Surveill 2011, 16. [pii=19776].
24. Baz M., Abed Y., Papenburg J., Bouhy X., Hamelin M.E., Boivin G. Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. N Engl J Med 2009, 361:2296-2297.
25. Ciancio B.C., Meerhoff T.J., Kramarz P., Bonmarin I., Borgen K., Boucher C.A., et al. Oseltamivir-resistant influenza A(H1N1) viruses detected in Europe during season 2007-8 had epidemiologic and clinical characteristics similar to co-circulating susceptible A(H1N1) viruses. Euro Surveill 2009, 14. [pii=19412].
26. European Centre for Disease Prevention and Control, Community Network of Reference Laboratories for Human Influenza (CNRL). CNRL Recommendation on strains for antiviral susceptibility testing: referral of influenza strains to WHO Collaborating Centre London; 2010. Available from the European Influenza Surveillance Network (EISN) Extranet Library. http://ecdc.europa.eu/.
27. Wetherall N.T., Trivedi T., Zeller J., Hodges-Savola C., McKimm-Breschkin J.L., Zambon M., et al. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J Clin Microbiol 2003, 41:742-750.
28. Thompson C.I., Lackenby A., Daniels R.S., McCauley J.W., Pereyaslov D., Broberg E.K., et al. Evaluation of influenza virus antiviral susceptibility testing in Europe: results from the first external quality assessment exercise. J Clin Virol 2013, 56:296-302.
29. Massart D.L., Smeyers-Verbeke J., Capron X., Schlesier K. Visual presentation of data by means of box plots. LC-GC Eur 2005, 18:215-218.
30. Royal Society of Chemistry. Robust statistics: a method of coping with outliers. Analytical Methods Committee Technical Brief 6; 2001. Available from: http://www.rsc.org/images/robust-statistics-technical-brief-6_tcm18-214850.pdf.
31. van der Vries E., Jonges M., Herfst S., Maaskant J., Van der Linden A., Guldemeester J., et al. Evaluation of a rapid molecular algorithm for detection of pandemic influenza A (H1N1) 2009 virus and screening for a key oseltamivir resistance (H275Y) substitution in neuraminidase. J Clin Virol 2010, 47:34-37.
32. Duwe S., Schweiger B. A new and rapid genotypic assay for the detection of neuraminidase inhibitor resistant influenza A viruses of subtype H1N1, H3N2, and H5N1. J Virol Methods 2008, 153:134-141.
33. Steain M.C., Dwyer D.E., Hurt A.C., Kol C., Saksena N.K., Cunningham A.L., et al. Detection of influenza A H1N1 and H3N2 mutations conferring resistance to oseltamivir using rolling circle amplification. Antiviral Res 2009, 84:242-248.
34. Duan S., Boltz D.A., Li J., Oshansky C.M., Marjuki H., Barman S., et al. Novel genotyping and quantitative analysis of neuraminidase inhibitor resistance-associated mutations in influenza a viruses by single-nucleotide polymorphism analysis. Antimicrob Agents Chemother 2011, 55:4718-4727.
35. Redlberger-Fritz M., Aberle S.W., Strassl R., Popow-Kraupp T. Rapid identification of neuraminidase inhibitor resistance mutations in seasonal influenza virus A(H1N1) A(H1N1)2009, and A(H3N2) subtypes by melting point analysis. Eur J Clin Microbiol Infect Dis 2012, 31:1593-1601.
36. Legoff J., Rousset D., Abou-Jaoudé G., Scemla A., Ribaud P., Mercier-Delarue S., et al. I223R mutation in influenza A(H1N1)pdm09 neuraminidase confers reduced susceptibility to oseltamivir and zanamivir and enhanced resistance with H275Y. PLoS One 2012, 7:e37095.
37. Baz M., Abed Y., McDonald J., Boivin G. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin Infect Dis 2006, 43:1555-1561.
38. Okomo-Adhiambo M., Nguyen H.T., Sleeman K., Sheu T.G., Deyde V.M., Garten R.J., et al. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses. Antiviral Res 2010, 85:381-388.